Clover Corporation (CLV) H1 2026 earnings summary

Executive summary

• Revenue for 1H FY26 reached $44.1 million, up $6.5 million or 17% year-over-year, driven by new customer acquisitions, growth in Europe and ANZ, and improved market conditions.

• Gross margin improved to 35.6%, up from 27.1%–30.4% in the prior year, reflecting a favorable product mix, operational improvements, and manufacturing efficiencies.

• EBITDA rose to $6.9 million, up $2.6 million year-over-year, supported by sales growth, new products, and better manufacturing performance.

• NPAT increased to $4.2 million, up $1.8 million or 75%–79% year-over-year, with growth attributed to new customers, higher sales, and improved margins.

• Strategic focus on product diversification and expansion into broader human nutrition segments is reducing reliance on single markets.

Financial highlights

• Revenue reached a record $44.1 million for the half, up 17% from the previous period.

• Gross profit increased by $5.5 million to $15.7 million year-over-year.

• EBITDA up 60% to $6.9 million year-over-year.

• NPAT up 75%–90% to $4.2 million year-over-year.

• EPS increased to 2.54 cents per share, up from 1.42 cents per share.

Outlook and guidance

• FY26 revenue guidance set at $92–96 million, reflecting confidence in continued growth and positive momentum into the second half.

• Guidance assumes stable geopolitical conditions and supply chains.

• CholineXcel® product trials and regulatory outcomes expected in July 2026.